PHARMACEUTICAL COMPOSITIONS FOR TREATING ANXIETY

Abstract

Pharmaceutical compositions or functional foods for treating anxiety comprising ginseng saponin (Rg1+Rb1), glycyrrhizic acid and jujuba cAMP. Experiments demonstrate that as compared with the preferred drug for treating diazepam in the art, the present invention has significant anxielytic efficacy.

Claims

1. A method for treating an anxiety disorder in a patient in need thereof, the method comprises administering to the patient an effective amount of a pharmaceutical composition comprising: 2˜24 parts by weight of a ginsenoside Rg1 and a ginsenoside Rb1; 3˜45 parts by weight of a glycyrrhiza related acid being one selected from a group consisting of a glycyrrhizic acid, a glycyrrhetinic acid and a combination thereof; and 0.003˜0.4 parts by weight of a jujuba cyclic adenosine monophosphate (jujuba cAMP).

2. The method according to claim 1, wherein the pharmaceutical composition comprises 4˜11 parts by weight of the ginsenoside Rg1 and the ginsenoside Rb1, 5˜14 parts by weight of the glycyrrhiza related acid and 0.01˜0.07 parts by weight of the jujuba cAMP.

3. The method according to claim 1, wherein the ginsenoside Rg1 and the ginsenoside Rb1 are extracted from a ginseng, the glycyrrhiza related acid is extracted from a liquorice, and the jujuba cAMP is extracted from a jujuba.

4. The method according to claim 3, wherein the jujuba is extracted by a first macroporous resin bound with an aldehyde group for obtaining a first extract having a first jujuba cAMP concentration, the first extract is further purified by a second macroporous resin bound with an aldehyde group for obtaining a second extract having a second jujuba cAMP concentration, and the second jujuba cAMP concentration is higher than the first jujuba cAMP concentration.

5. The method according to claim 1, wherein the pharmaceutical composition further comprising an additive.

6. The method according to claim 1, wherein the pharmaceutical composition having a dosage form selected from a group consisting of a tablet, a capsule, a powder, a pill, a dust, a solution, a microcapsule, a suspension, an emulsion, a particle, a dropping pill, and a roll.

7. The method according to claim 1, wherein the pharmaceutical composition being manufactured as one of a healthcare food and a supplement.

8. A method for treating an anxiety disorder in a patient in need thereof, the method comprises administering to the patient an effective amount of a pharmaceutical composition comprising: 2˜24 parts by weight of a ginsenoside Rg1 and a ginsenoside Rb1; and 3˜45 parts by weight of a glycyrrhiza related acid being one selected from a group consisting of a glycyrrhizic acid, a glycyrrhetinic acid and a combination thereof.

9. The method according to claim 8, wherein the pharmaceutical composition comprising 4˜11 parts by weight of the ginsenoside Rg1 and the ginsenoside Rb1, and 5˜14 parts by weight of the glycyrrhiza related acid.

10. The method according to claim 8, wherein the ginsenoside Rg1 and the ginsenoside Rb1 are extracted from a ginseng, and the glycyrrhiza related acid is extracted from a liquorice.

11. The method according to claim 8, wherein the pharmaceutical composition further comprising an additive.

12. The method according to claim 8, wherein the pharmaceutical composition having a dosage form selected from a group consisting of a tablet, a capsule, a powder, a pill, a dust, a solution, a microcapsule, a suspension, an emulsion, a particle, a dropping pill, and a roll.

13. The method according to claim 8, wherein the pharmaceutical composition being manufactured as one of a healthcare food and a supplement.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0032] The above objectives and advantages of the present invention will become more readily apparent to those ordinarily skilled in the art after reviewing the following detailed descriptions and accompanying drawings, in which:

[0033] FIG. 1 is a flowchart showing a preparation method of a pharmaceutical composition in accordance with a first preferred embodiment of the present invention;

[0034] FIG. 2 is a flowchart showing a preparation method of a pharmaceutical composition in accordance with a second preferred embodiment of the present invention;

[0035] FIG. 3 is a flowchart showing a preparation method of a pharmaceutical composition in accordance with a third preferred embodiment of the present invention;

[0036] FIG. 4 is a flowchart showing a preparation method of a pharmaceutical composition in accordance with a fourth preferred embodiment of the present invention;

[0037] FIG. 5 is a flowchart showing a preparation method of a pharmaceutical composition in accordance with a fifth preferred embodiment of the present invention; and

[0038] FIG. 6 is a flowchart showing a preparation method of a pharmaceutical composition in accordance with a sixth preferred embodiment of the present invention.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0039] The present invention will now be described more specifically with reference to the following Embodiments. It is to be noted that the following descriptions of preferred Embodiments of this invention are presented herein for purpose of illustration and description only; it is not intended to be exhaustive or to be limited to the precise form disclosed.

[0040] In order to accomplish the purpose of the present invention, the technical schemes of the present invention are particularly provided as follows.

Example 1

[0041] The pharmaceutical composition of the present invention for treating anxiety disorder is manufactured from the raw materials of ginseng and liquorice.

Example 2

[0042] The pharmaceutical composition of the present invention for treating anxiety disorder is manufactured from the raw materials having 4˜58 parts by weight of ginseng and 2˜28 parts by weight of liquorice.

Example 3

[0043] The pharmaceutical composition of the present invention for treating anxiety disorder is manufactured from the raw materials having 10˜26 parts by weight of ginseng and 5˜13 parts by weight of liquorice.

Example 4

[0044] The pharmaceutical composition of the present invention for treating anxiety disorder is manufactured from the raw materials of ginseng, liquorice and jujuba.

Example 5

[0045] The pharmaceutical composition of the present invention for treating anxiety disorder is manufactured from the raw materials having 4˜58 parts by weight of ginseng, 2˜28 parts by weight of liquorice and 2˜38 parts by weight of jujuba.

Example 6

[0046] The pharmaceutical composition of the present invention for treating anxiety disorder is manufactured from the raw materials having 10˜26 parts by weight of ginseng, 5˜13 parts by weight of liquorice and 4˜16 parts by weight of jujuba.

Example 7

[0047] The pharmaceutical composition of the present invention for treating anxiety disorder is manufactured from the raw materials of ginsenoside Rg1 and Rb1, and glycyrrhizic acid (or glycyrrhetinic acid).

Example 8

[0048] The pharmaceutical composition of the present invention for treating anxiety disorder is manufactured from 2˜24 parts by weight of ginsenoside Rg1 and Rb1, and 3˜45 parts by weight of glycyrrhizic acid (or glycyrrhetinic acid).

Example 9

[0049] The pharmaceutical composition of the present invention for treating anxiety disorder is manufactured from 4˜11 parts by weight of ginsenoside Rg1 and Rb1, and 5˜14 parts by weight of glycyrrhizic acid (or glycyrrhetinic acid).

Example 10

[0050] The pharmaceutical composition of the present invention for treating anxiety disorder is manufactured from the raw materials of the ginseng extract having the above-mentioned parts by weight of ginsenoside Rg1 and Rb1, and the liquorice extract having the above-mentioned parts by weight of glycyrrhizic acid.

Example 11

[0051] The pharmaceutical composition of the present invention for treating anxiety disorder is manufactured from the raw materials of ginsenoside Rg1 and Rb1, glycyrrhizic acid (or glycyrrhetinic acid) and jujuba cAMP.

Example 12

[0052] The pharmaceutical composition of the present invention for treating anxiety disorder is manufactured from the raw materials having 2˜24 parts by weight of ginsenoside Rg1 and Rb1, 3˜45 parts by weight of glycyrrhizic acid (or glycyrrhetinic acid) and 0.003˜0.4 parts by weight of jujuba cAMP.

Example 13

[0053] The pharmaceutical composition of the present invention for treating anxiety disorder is manufactured from the raw materials having 4˜11 parts by weight of ginsenoside Rg1 and Rb1, 5˜14 parts by weight of glycyrrhizic acid (or glycyrrhetinic acid) and 0.01˜0.07 parts by weight of jujuba cAMP.

Example 14

[0054] The pharmaceutical composition of the present invention for treating anxiety disorder is manufactured from the raw materials of the ginseng extract having the above-mentioned parts by weight of ginsenoside Rg1 and Rb1, the liquorice extract having the above-mentioned parts by weight of glycyrrhizic acid, and the jujuba extract having the above-mentioned parts by weight of jujuba cAMP.

Example 15

[0055] The pharmaceutical composition of the present invention is provided, wherein the raw material having jujuba cAMP is the second extract described as follows. First, jujuba is extracted for obtaining the first extract, then the first extract is further extracted for obtaining the second extract, wherein the jujuba cAMP concentration of the second extract is higher than that of the first extract.

Example 16

[0056] The preparation method of the pharmaceutical composition including the raw material of jujuba cAMP is provided. The preparation method thereof includes the steps as follows.

[0057] (a) Jujuba is extracted for obtaining a first extract; and

[0058] (b) the first extract is further purified for obtaining a second extract, and the jujuba cAMP concentration of the second extract is higher than that of the first extract.

Example 17

[0059] In the aforementioned preparation method, the step (b) is processed by chromatographing, absorbing and separating jujuba cAMP of the first extract with the macroporous resin bound with the aldehyde group.

Example 18

[0060] In the aforementioned preparation method, the step (b) is processed by chromatographing, absorbing and separating jujuba cAMP of the first extract with the OU-2 macroporous resin bound with the aldehyde group.

Example 19

[0061] In the aforementioned preparation method, the step (b) is processed by chromatographing, absorbing and separating jujuba cAMP of the first extract with the ME-2 macroporous resin bound with the aldehyde group.

Example 20

[0062] The pharmaceutical composition of the present invention includes the pharmacologically acceptable carriers or additives.

Example 21

[0063] The pharmaceutical composition of the present invention can be manufactured as a dosage form, and the dosage forms is selected from any one of a tablet, a capsule, a powder, a pill, a dust, a solution, a microcapsule, a suspension, an emulsion, a particle, a dropping pill, a roll, and the pharmacologically oral pharmaceutical dosage form.

Example 22

[0064] The pharmaceutical composition of the present invention further can be manufactured as healthcare food and nutrient supplements.

[0065] In order to accomplish the purpose of the present invention, the preparation methods of the pharmaceutical composition are provided as follows.

Method 1

[0066] The pharmaceutical composition of the present invention for treating anxiety disorder is manufactured from the extract having ginsenoside Rg1 and Rb1 and glycyrrhizic acid, wherein the extract is extracted and purified from the raw materials having 4˜58 parts by weight of ginseng and 2˜28 parts by weight of liquorice.

Method 2

[0067] The pharmaceutical composition of the present invention for treating anxiety disorder is manufactured from the extract having ginsenoside Rg1 and Rb1 and glycyrrhizic acid, wherein the extract is extracted and purified from the raw materials having 10˜26 parts by weight of ginseng and 5˜13 parts by weight of liquorice.

[0068] Method 3

[0069] The pharmaceutical composition of the present invention for treating anxiety disorder is manufactured from the extract having ginsenoside Rg1 and Rb1, glycyrrhizic acid and jujuba cAMP, wherein the extract is extracted and purified from the raw materials having 4.about.58 parts by weight of ginseng, 2˜28 parts by weight of liquorice and 2˜38 parts by weight of jujuba.

Method 4

[0070] The pharmaceutical composition of the present invention for treating anxiety disorder is manufactured from the extract having ginsenoside Rg1 and Rb1, glycyrrhizic acid and jujuba cAMP, wherein the extract is extracted and purified from the raw materials having 10˜26 parts by weight of ginseng, 5˜13 parts by weight of liquorice and 4˜16 parts by weight of jujuba.

Method 5

[0071] The pharmaceutical composition of the present invention for treating anxiety disorder is manufactured from (1) the extracts having ginsenoside Rg1 and Rb1 extracted and purified from ginseng, and glycyrrhizic acid extracted and purified from liquorice; or (2) the prepared raw materials having ginsenoside Rg1 and Rb1, and glycyrrhizic acid (or glycyrrhetinic acid).

Method 6

[0072] The pharmaceutical composition of the present invention for treating anxiety disorder is manufactured from the raw materials having 2˜24 parts by weight of ginsenoside Rg1 an Rb1, and 3˜45 parts by weight of glycyrrhizic acid (or glycyrrhetinic acid).

Method 7

[0073] The pharmaceutical composition of the present invention for treating anxiety disorder is manufactured from the raw materials having 4˜11 parts by weight of ginsenoside Rg1 an Rb1, and 5˜14 parts by weight of glycyrrhizic acid (or glycyrrhetinic acid).

Method 8

[0074] The pharmaceutical composition of the present invention for treating anxiety disorder is manufactured from (1) the extracts having ginsenoside Rg1 and Rb1, glycyrrhizic acid and jujuba cAMP respectively extracted and purified from ginseng, liquorice and jujuba; or (2) the prepared raw materials having ginsenoside Rg1 and Rb1, glycyrrhizic acid (or glycyrrhetinic acid) and jujuba cAMP.

Method 9

[0075] The pharmaceutical composition of the present invention for treating anxiety disorder is manufactured from the raw materials having 2˜24 parts by weight of ginsenoside Rg1 an Rb1, 3˜45 parts by weight of glycyrrhizic acid (or glycyrrhetinic acid) and 0.003˜0.4 parts by weight of jujuba cAMP.

Method 10

[0076] The pharmaceutical composition of the present invention for treating anxiety disorder is manufactured from the raw materials having 4˜11 parts by weight of ginsenoside Rg1 an Rb1, 5˜14 parts by weight of glycyrrhizic acid (or glycyrrhetinic acid) and 0.01˜0.07 parts by weight of jujuba cAMP.

Method 11

[0077] The preparation method of the pharmaceutical composition including the raw material of jujuba cAMP is provided. The preparation method thereof includes the steps as follows.

[0078] (a) Jujuba is extracted for obtaining a first extract; and

[0079] (b) the first extract is further purified for obtaining a second extract, and the jujuba cAMP concentration of the second extract is higher than that of the first extract.

Method 12

[0080] In the aforementioned preparation method, the step (b) is processed by chromatographing, absorbing and separating jujuba cAMP of the first extract with the macroporous resin bound with the aldehyde group.

Method 13

[0081] In the aforementioned preparation method, the step (b) is processed by chromatographing, absorbing and separating jujuba cAMP of the first extract with the OU-2 macroporous resin bound with the aldehyde group.

Method 14

[0082] In the aforementioned preparation method, the step (b) is processed by chromatographing, absorbing and separating jujuba cAMP of the first extract with the ME-2 macroporous resin bound with the aldehyde group.

Method 15

[0083] The pharmaceutical composition of the present invention includes the pharmacologically acceptable carriers or additives.

Method 16

[0084] The pharmaceutical composition of the present invention can be manufactured as a dosage form, and the dosage forms is selected from any one of a tablet, a capsule, a powder, a pill, a dust, a solution, a microcapsule, a suspension, an emulsion, a particle, a dropping pill, a roll, and the pharmacologically oral pharmaceutical dosage form.

Method 17

[0085] The raw materials described in the present invention can be manufactured as the medicines, healthcare food and nutrient supplements for treating anxiety disorder in accordance with the Good Manufacturing Practice (GMP) pharmaceutical standards and the method of healthcare food producing/manufacturing standards.

THE PREFERRED EMBODIMENTS

[0086] The present invention is further illustrated as follows by combining the figures and the preferred embodiments.

Embodiment 1

[0087] Please refer to FIG. 1, which is the flowchart showing a preparation method of a pharmaceutical composition in accordance with a first preferred embodiment of the present invention. In FIG. 1, after 20 kg of ginseng (101) is fractured, the fractured ginseng is heated to extract by 70% of the ethanol solution. The extracted ginseng is separated and purified by chromatography, and dried, and 0.8 kg of the ginseng extract having 120 g of ginsenoside Rg1 and Rb1 is obtained (102). Further, after 10 kg of liquorice (103) is fractured, the fractured liquorice is soaked at room temperature for 12 hours. The soaked liquorice is extracted by decoction and alcohol sedimentation, concentrated and dried, and 2 kg of the liquorice extract having 200 g of glycyrrhizic acid is obtained (104). Next, 150 g of the obtained ginseng extract and 200 g of the obtained liquorice extract are pulverized and mixed, and 350 g of the pharmaceutical composition (containing 22.5 g of ginsenoside Rg1 and Rb1, and 20 g of glycyrrhizic acid) of the present invention is obtained (105).

Embodiment 2

[0088] Please refer to FIG. 2, which is the flowchart showing a preparation method of a pharmaceutical composition in accordance with a second preferred embodiment of the present invention. In FIG. 2, after the prepared 3.96 g of glycyrrhetinic acid having 96% purity (202) and 200 g of the ginseng extract obtained in Embodiment 1 (201) are pulverized and mixed, 203.96 g of the pharmaceutical composition (containing 30 g of ginsenoside Rg1 and Rb1, and 3.8 g of glycyrrhetinic acid) of the present invention is obtained (203).

Embodiment 3

[0089] Please refer to FIG. 3, which is the flowchart showing a preparation method of a pharmaceutical composition in accordance with a third preferred embodiment of the present invention. In FIG. 3, after 3.4 g of the prepared ginsenoside Rg1 having 90% purity (301), 7.8 g of the prepared ginsenoside Rb1 having 90% purity (302) and 36.8 g of glycyrrhizic acid having 90% purity (303) are pulverized and mixed, 48 g of the pharmaceutical composition (containing 10 g of ginsenoside Rg1 and Rb 1, and 35 g of glycyrrhizic acid) of the present invention is obtained (304).

Embodiment 4

[0090] Please refer to FIG. 4, which is the flowchart showing a preparation method of a pharmaceutical composition in accordance with a fourth preferred embodiment of the present invention. In FIG. 4, 10 kg of jujuba (401) is fractured and soaked in the water at room temperature, then the soaked jujuba is extracted by decoction and alcohol sedimentation for obtaining the jujuba extract, which is further absorbed and separated by the OU-2 and ME-2 macroporous resins sequentially, and dried. Thirty (30) g of the jujuba extract containing 0.3 g of jujuba cAMP is obtained to be the raw material for preparing the medicine of the present invention (402).

[0091] Afterwards, after 150 g of the ginseng extract and 200 g of the liquorice extract obtained in Embodiment 1 are pulverized and mixed with 3 g of the above-mentioned jujuba extract, and 353 g of the pharmaceutical composition (containing 22.5 g of ginsenoside Rg1 and Rb1, 20 g of glycyrrhizic acid and 0.03 g of jujuba cAMP) of the present invention is obtained (403).

Embodiment 5

[0092] Please refer to FIG. 5, which is the flowchart showing a preparation method of a pharmaceutical composition in accordance with a fifth preferred embodiment of the present invention. In FIG. 5, after 150 g of the ginseng extract (501) and 200 g of the liquorice extract (502) obtained in Embodiment 1 respectively are pulverized and mixed with 0.5 g of the jujuba extract obtained in Embodiment 4 (503), 350.5 g of the pharmaceutical composition (containing 22.5 g of ginsenoside Rg1 and Rb1, 20 g of glycyrrhizic acid and 0.005 g of jujuba cAMP) of the present invention is obtained (504).

Embodiment 6

[0093] Please refer to FIG. 6, which is the flowchart showing a preparation method of a pharmaceutical composition in accordance with a sixth preferred embodiment of the present invention. In FIG. 6, after 6.8 g of the prepared ginsenoside Rg1 having 90% purity (601), 15.6 g of the prepared ginsenoside Rb1 having 90% purity (602), 26 g of glycyrrhetinic acid having 96% purity (603) and 10 g of the jujuba extract obtained in Embodiment 4 (604) are pulverized and mixed, 58.4 g of the pharmaceutical composition (containing 20 g of ginsenoside Rg1 and Rb1, 25 g of glycyrrhetinic acid and 0.1 g of jujuba cAMP) of the present invention is obtained (605).

Experiment 1

[0094] The Influence of Embodiment 1 in the Light-Dark Transition Experiment of the Mouse

[0095] 1.1 Experimental animals: Kunming (KM) mice, male, 24˜26 g of body weight, secondary, are provided by the Experimental Animal Science Department of Capital Medical University, Beijing.

[0096] 1.2 Experimental pharmaceuticals: The pharmaceutical of Embodiment 1 is provided by Beijing Wonner Biotech. Ltd. Co., and Diazepam is the product of Tianjin Jinhuei Amino Acid Co. Ltd.

[0097] 1.3 Experimental equipment: Self-made light-dark transition box.

[0098] 1.4 Dose designs: 1. High dose of Embodiment 4 (80 mg/kg/d); 2. middle dose of Embodiment 4 (40 mg/kg/d); and 3. low dose of Embodiment 4 (20 mg/kg/d).

[0099] 1.5 Experimental Method and Result:

[0100] 1.5.1 Group division and administration of drug: The mice are grouped randomly as 5 groups, and 10 mice are in each group. 1. High dose of Embodiment 1 (80 mg/kg); 2. middle dose of Embodiment 1 (40 mg/kg); 3. low dose of Embodiment 1 (20 mg/kg); 4. Diazepam (2.5 mg/kg); and 5. physiological saline (normal saline, NS). The drugs are fed into the mouse stomach once every day, and the mouse is administered for continuous 7 days. During the period of administration, the mouse eats and drinks freely, and the experiment is proceeded after 1 hour of the last administration of drug on the eighth day.

[0101] 1.5.2 Experimental Method.

[0102] Mouse light-dark transition test: The dark chamber occupies one third of the light-dark transition chamber (44 cm×21 cm×21 cm), and the top is capped. The light chamber occupies two third thereof and is illuminated brightly. A door between two chambers is disposed for the passage of the mouse. The mouse is placed in the center of the light chamber when the experiment begins, and the mouse's back faces the dark chamber. The times that the mouse enters into the dark chamber and returns to the light chamber within 10 minutes are determined, and the times thereof are the index for evaluating the anti-anxiety function of the drugs.

[0103] 1.5.3 Statistic calculation: The experimental data are represented as X±SD, and the experimental result is calculated as one-way analysis of variance (one-way ANOVA) by SPSS 11.5 statistic software.

[0104] 1.5.4 Experimental result: Please refer to Table 1.

TABLE-US-00001 TABLE 1 The influence of Embodiment 1 on the times of the mouse light-dark transition experiment Animal Times of passing from dark Group number chamber to light chamber High dose of Embodiment 1 10 11.2 ± 3.84* Middle dose of Embodiment 1 10  13.1 ± 5.38** Low dose of Embodiment 1 10  13.5 ± 4.65** Diazepam 10 11.3 ± 4.54* Normal saline (NS) 10 6.2 ± 4.32 In comparison with NS group: *P < 0.005, and **P < 0.01.

[0105] 1.6 Description: The light-dark transition experiment adopted in the present experiment is built up on the basis that the mouse congenitally hates the bright light and the voluntary exploring behavior to the new environment. The clinical medicine (Diazepam) for treating anxiety in human beings and the Embodiment 1 have excellent correlation on improving the function of the increasing voluntary exploring behavior on this mouse model. According to the above experiment, it can be found that the high, middle and low doses of Embodiment 1 of the present invention and Diazepam all significantly increase the times that the mouse passes from the dark chamber to the light chamber, and have statistical meanings while comparing with the physiological saline. The experimental result has proven that the Embodiment 1 has anti-anxiety effect.

[0106] 1.7 Conclusion: According to the above experimental result, it shows that the high, middle and low doses of Embodiment 1 of the present invention and Diazepam all significantly increase the times that the mouse passes from the dark chamber to the light chamber. The result shows the Embodiment 1 having anti-anxiety effect.

Experiment 2

[0107] The Influence of Embodiment 4 in the Mouse Light-Dark Transition Experiment

[0108] 2.1 Experimental animals: Kunming (KM) mice, male, 24˜26 g of body weight, secondary, are provided by the Experimental Animal Science Department of Capital Medical University, Beijing.

[0109] 2.2 Experimental pharmaceuticals: The pharmaceutical of Embodiment 4 is provided by Beijing Wonner Biotech. Ltd. Co., and Diazepam is the product of Tianjin Jinhuei Amino Acid Co. Ltd.

[0110] 2.3 Experimental equipment: Self-made light-dark transition box.

[0111] 2.4 Dose designs: 1. High dose of Embodiment 4 (80 mg/kg/d); 2. middle dose of Embodiment 4 (40 mg/kg/d); and 3. low dose of Embodiment 4 (20 mg/kg/d).

[0112] 2.5 Experimental Method and Result:

[0113] 2.5.1 Group division and administration of drug: The mice are grouped randomly as 5 groups, and 10 mice are in each group. 1. High dose of Embodiment 4 (80 mg/kg); 2. middle dose of Embodiment 4 (40 mg/kg); 3. low dose of Embodiment 4 (20 mg/kg); 4. Diazepam (2.5 mg/kg); and 5. physiological saline (normal saline, NS). The drugs are fed into the mouse stomach once every day, and the mouse is administered for continuous 7 days. During the period of administration, the mouse eats and drinks freely, and the experiment is proceeded after 1 hour of the last administration of drug on the eighth day.

[0114] 2.5.2 Experimental Method:

[0115] Mouse light-dark transition test: The dark chamber occupies one third of the light-dark transition chamber (44 cm×21 cm×21 cm), and the top is capped. The light chamber occupies two third thereof and is illuminated brightly. A door between two chambers is disposed for the passage of the mouse. The mouse is placed in the center of the light chamber when the experiment begins, and the mouse's back faces the dark chamber. The times that the mouse enters into the dark chamber and returns to the light chamber within 10 minutes are determined, and the times thereof are the index for evaluating the anti-anxiety function of the drugs.

[0116] 2.5.3 Statistic calculation: The experimental data are represented as X±SD, and the experimental result is calculated as one-way ANOVA by SPSS 11.5 statistic software.

[0117] 2.5.4 Experimental result: Please refer to Table 2.

TABLE-US-00002 TABLE 2 The influence of Embodiment 4 on the times of the mouse light-dark transition experiment Animal Times of passing from dark Group number chamber to light chamber High dose of Embodiment 4 10 11.6 ± 2.53* Middle dose of Embodiment 4 10  13.9 ± 3.76** Low dose of Embodiment 4 10  13.4 ± 4.12** Diazepam 10 11.7 ± 4.47* Normal saline (NS) 10 6.8 ± 3.85 In comparison with NS group: *P < 0.005, and **P < 0.01.

[0118] 2.6 Description: The light-dark transition experiment adopted in the present experiment is built on the basis that the mouse congenitally hates the bright light and the voluntary exploring behavior to the new environment. The clinical pharmaceutical (Diazepam) for treating anxiety in human beings and the Embodiment 4 have excellent correlation on improving the function of the increasing voluntary exploring behavior of the mouse on this model. According to the above experiment, it can be found that the high, middle and low doses of Embodiment 4 of the present invention and Diazepam all significantly increase the times that the mouse passes from the dark chamber to the light chamber, and have statistical meanings while comparing with the normal saline. The experimental result has proven that the Embodiment 4 has anti-anxiety effect.

[0119] 2.7 Conclusion: According to the above experimental result, the high, middle and low doses of Embodiment 4 of the present invention and Diazepam all significantly increase the times that the mouse passes from the dark chamber to the light chamber. The result demonstrates the Embodiment 4 has anti-anxiety function.

INDUSTRIAL USEFULNESS

[0120] The application scope of the pharmaceutical composition of the present invention for treating anxiety disorder lies in that:

[0121] 1. The described pharmaceutical composition of the present invention for treating anxiety disorder can include the pharmacologically acceptable additives;

[0122] 2. The described pharmaceutical composition of the present invention for treating anxiety disorder can be manufactured as the known dosage forms, such as powder, capsule, tablet, etc.; and

[0123] 3. The described pharmaceutical composition of the present invention for treating anxiety disorder can be manufactured as the healthcare food for treating depression.

[0124] While the invention has been described in terms of what is presently considered to be the most practical and preferred Embodiments, it is to be understood that the invention needs not be limited to the disclosed Embodiments. On the contrary, it is intended to cover various modifications and similar arrangements included within the spirit and scope of the appended claims, which are to be accorded with the broadest interpretation so as to encompass all such modifications and similar structures.